In a deal worth up to $1 billion, Ideaya Biosciences Inc. is in-licensing Jiangsu Hengrui Pharmaceuticals Co. Ltd.’s SHR-4849, a phase I DLL3-targeting opo-I-payload antibody-drug conjugate (ADC).

Prostatic-specific antigen (PSA) is commonly used as a screening tool for prostate cancer but presents limited sensitivity and specificity. Therefore, research efforts are focused on searching for ...

After the funding feast sparked by the pandemic, European biotech has emerged from the famine that followed, with venture capital raised this year finally exceeding the 2020 total.After the funding ...

Epirium Bio Inc. has obtained IND clearance from the FDA for MF-300, a first-in-class orally administered, 15-hydroxyprostaglandin dehydrogenase (15-PGDH) enzyme inhibitor.

The first round of the U.S.’ Medicare negotiations accounted for a lot of digital ink and headlines in 2024. Next year is sure to bring more of the same as Medicare is to announce up to 15 Part D ...

South Korea’s Ministry of Food and Drug Safety cleared Acryl Inc.’s Acryl-D01 as the country’s first AI-based digital therapeutic software solution to aid depression screening and diagnosis on Dec. 20 ...

In a deal worth $100 million up front and up to $1.25 billion in milestone payments, Bioarctic AB licensed its pyroglutamate-amyloid-β (pyroglutamate-Aβ) antibody program to Bristol Myers Squibb Co.

Deciphera Pharmaceuticals LLC has divulged eukaryotic translation initiation factor 2-α kinase 3 (PERK) and/or GCN2 inhibitors reported to be useful for the treatment of cancer and amyloidosis.

In the 1970s, scientists from several countries proposed to reconstruct, one by one, all the neurons in the brain as they appear under an electron microscope. They started with a small worm.

Deepcure Inc. has discovered potent, selective oral small-molecule inhibitors of STAT6. These next-generation STAT6 inhibitors have demonstrated promising oral bioavailability, cell permeability and ...

The regular use of agonists of the μ-opioid receptor for acute pain relief usually leads to tolerance, respiratory depression, constipation and importantly, abuse potential.

Bio-path Holdings Inc. has conducted preclinical studies of BP-1001-A, a drug product modification of prexigebersen, confirming its effectiveness in affecting insulin signaling for the potential ...